Abstract: Methods of determining the erythroid prognosis of an anemia, methods of treating a blood disorder in a subject comprising an anemia, and methods of treating a blood disorder in a subject comprising an expanded erythron are all provided.
Type:
Application
Filed:
July 10, 2019
Publication date:
February 13, 2020
Applicant:
Albert Einstein College of Medicine
Inventors:
Andrew Chow, Paul S. Frenette, Miriam Merad
Abstract: Methods and systems for high-throughput Identification of receptor: ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.
Type:
Application
Filed:
July 25, 2018
Publication date:
January 9, 2020
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Steven C. Almo, Ronald D. Seidel, III, Brandan S. Hillerich, Sarah C. Garrett-Thomson, James D. Love
Abstract: A method for improving the performance of a fluorescence microscopy imaging system and for correcting chromatic aberration of an optical objective in a fluorescence microscopy system.
Type:
Application
Filed:
January 19, 2018
Publication date:
November 7, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Robert H. Singer, Carolina Eliscovich, Shailesh M. Shenoy
Abstract: Methods for treating diabetes or obesity are provided comprising administering to the subject an amount of an agent that binds a central nervous system FGF receptor homodimer.
Abstract: A product comprising a stent for a human blood vessel which comprises (i) a scaffold which is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, or (ii) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a Wnt/p-catenin pathway, and methods of use to reduce the risk of restenosis.
Type:
Grant
Filed:
November 5, 2014
Date of Patent:
October 15, 2019
Assignee:
Albert Einstein College of Medicine
Inventors:
Nicholas Ernst Smit Sibinga, Dario Fernando Riascos-Bernal
Abstract: Nucleic acid molecules encoding monomeric near-infrared fluorescent proteins, variants and derivatives thereof are provided, as well as proteins and peptides encoded by these nucleic acids. Also provided are proteins that are substantially similar to, or derivatives, homologues, or mutants of, the above-referenced specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, specifically split fluorescent proteins. In addition, host-cells, stable cell lines and transgenic organisms comprising above-referenced nucleic acid molecules are provided. The invention also refers to methods of making and using monomeric fluorescent proteins derived from bacterial phytochromes. The subject protein and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells or cell organelles, and for detecting protein-protein interactions. Finally, kits for use in such methods and applications are provided.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
October 15, 2019
Assignee:
Albert Einstein College of Medicine
Inventors:
Vladislav V. Verkhusha, Daria M. Shcherbakova, Mikhail Baloban
Abstract: The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
October 8, 2019
Assignees:
Albert Einstein College of Medicine, The Governing Council of the University of Toronto, The Government of the United States as Represented by the Secretary of the Army
Inventors:
Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
Abstract: Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation.
Abstract: The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
October 1, 2019
Assignees:
Vitrisa Therapeutics, Inc., Albert Einstein College of Medicine
Inventors:
Carl Erickson, Christopher P. Rusconi, Kevin G. McLure, Matthew Levy, Arijit Bhowmick
Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
Type:
Application
Filed:
December 5, 2017
Publication date:
September 26, 2019
Applicants:
Microbiotix, Inc., Albert Einstein College Of Medicine, Inc., The Govermnment Of The United States As Represented By The Secretary Of
The Army
Inventors:
Terry L. Bowlin, Donald T. Moir, Kartik Chandran, John M. Dye, John D. Williams, Zachary D. Aron, Jay P. Barbor, Kelly N. Lively, Peter J. Nash, Debra M. Mills, Arnab Basu
Abstract: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.
Type:
Application
Filed:
February 22, 2019
Publication date:
September 19, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Type:
Application
Filed:
March 13, 2019
Publication date:
August 29, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
August 27, 2019
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Type:
Grant
Filed:
May 4, 2016
Date of Patent:
August 13, 2019
Assignee:
Albert Einstein College of Medicine
Inventors:
Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.
Abstract: The present invention addresses a need for antibodies useful for filovirus infections.
Type:
Application
Filed:
September 18, 2018
Publication date:
June 20, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCEL OF THE UNIVERSITY OF TORONTO, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Inventors:
Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
Abstract: Methods for increasing somatic hypermutation of antibodies, especially in vitro expression of an isolated retroviral protein in an isolated mammalian immunoglobulin-producing cell, are provided.